



# Care Is Calling

You thrive on making a difference.

This RSV season, continue making a difference by prescribing SYNAGIS® (palivizumab), the only prophylaxis against RSV, to prevent serious RSV disease requiring hospitalisation in high-risk infants.<sup>1,2</sup>

## RESPIRATORY SYNCYTIAL VIRUS IS REEMERGING. BE PREPARED. STAY VIGILANT


### IMPACT OF COVID 19 ON RSV INFECTION



- **Public health measures to reduce COVID-19** circulation resulted in **declining rates of RSV** infection across the globe in 2020<sup>3-5</sup>.
- This resulted in an increasing number of **infants who have never been exposed** to these common viruses<sup>6</sup>

**SYNAGIS®**  
PALIVIZUMAB 

# RSV CHALLENGES FOR WINTER 2021-2022 AND BEYOND



The loss of population immunity to RSV amongst young children may create a larger susceptible population that is potentially likely to have a larger outbreak this winter.<sup>7</sup>

Our reasonable worst-case scenario modelling similarly suggests that RSV levels could rise rapidly following relaxation of behavioural and environmental interventions, with a peak outbreak in early autumn of between 1.5 and 2 times the magnitude of a 'normal' year.<sup>7,8</sup>

Outbreaks of RSV in the autumn and influenza in the winter could be around **twice the magnitude of a 'normal' year, and might overlap** (at least partially) with a peak in COVID-19 infections.<sup>7</sup>



THE OFFICIAL NEWSMAGAZINE OF THE AMERICAN ACADEMY OF PEDIATRICS

## AAP News

The AAP interim guidance on administration of palivizumab during this delayed season is the same as for a typical season: Consider administering the humanized monoclonal antibody in up to five monthly doses to prevent RSV in high-risk infants and children in areas experiencing high rates of the virus.<sup>9</sup>



## STAY VIGILANT AND ADMINISTER RSV PROPHYLAXIS NOW TO PREVENT RSV IN HIGH-RISK INFANTS.

RSV: Respiratory syncytial virus

### References:

1. Synagis® (palivizumab). Summary of Product Characteristics
2. Goldstein M, et al. Neonatology Today. 2017;12(10):1-27.
3. Nagakumar P, et al. Eur J Pediatr. 2021;180(6):1975-1979.
4. Baker R, et al. 2020;117(48):30547-30553.
5. Hodjat P, et al. Microbiol Spectr. 2021;9(2):e00043021.
6. NHS England Primary Care bulletins – Issue 135: 8 June 2021. Available at: <https://www.england.nhs.uk/coronavirus/primary-care/other-resources/primary-care-bulletin/june-2021/>. Access date: January 2022.
7. Mahese E. BMJ. 2021;374:n1802.
8. Covid-19: Preparing the future. Looking ahead to winter 2021-22 and beyond. The Academy of Medical Sciences. Available at: <https://acmedsci.ac.uk/file-download/4747802>. Accessed, January 2022.
9. What's in the news: New Guidance on RSV during delayed season. Pediatric Infectious Diseases Society. Available at: <https://pids.org/2021/08/23/whats-in-the-news-new-guidance-on-rsv-during-delayed-season/>. Accessed, January 2022.

Please reach out to AstraZeneca for Full Prescribing Information.

### For Gulf:

For Adverse Events, please contact AZ Patient Safety Team through any of the channels below: Ph: +97143624888, or E-mail: [Patientsafety-azgulf@astrazeneca.com](mailto:Patientsafety-azgulf@astrazeneca.com), or Web: <https://contactazmedical.astrazeneca.com>. For Medical Information Requests: Please contact AZ Medical Information Team through any of the channels below: Phone: +97143624888, or Email: [gulf-medicalinfo@astrazeneca.com](mailto:gulf-medicalinfo@astrazeneca.com), or Web: <https://contactazmedical.astrazeneca.com>

### For Saudi:

For Medical information please send an email to [medinfo-ksa@astrazeneca.com](mailto:medinfo-ksa@astrazeneca.com)  
For AE reporting send email to [ksa.ae@astrazeneca.com](mailto:ksa.ae@astrazeneca.com)

**AstraZeneca** 

### For Gulf:

AstraZeneca FZ LLC Gulf  
P.O. Box: 505070 Dubai, UAE; Dubai Healthcare City,  
Building 27, Block D 2nd Floor;  
Tel: +971(4)362 4888, Fax: +971(4)362 4898/9

### For Saudi:

Al-Nakhla Tower - Floor 13th Ath Thumamah, Road - Al  
Sahafa District. 7198 Unit No. 20 Riyadh 13315 – 3642.  
Tel: +966 (011) 22 492 00; Fax: +966 (011) 22 492 91